Oliver Hoffmann

2.6k total citations
81 papers, 1.7k citations indexed

About

Oliver Hoffmann is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Oliver Hoffmann has authored 81 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 28 papers in Cancer Research and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Oliver Hoffmann's work include Medical Imaging Techniques and Applications (19 papers), Cancer Cells and Metastasis (17 papers) and Radiomics and Machine Learning in Medical Imaging (16 papers). Oliver Hoffmann is often cited by papers focused on Medical Imaging Techniques and Applications (19 papers), Cancer Cells and Metastasis (17 papers) and Radiomics and Machine Learning in Medical Imaging (16 papers). Oliver Hoffmann collaborates with scholars based in Germany, United States and Switzerland. Oliver Hoffmann's co-authors include Rainer Kimmig, Sabine Kasimir‐Bauer, Tanja Fehm, D. Wallwiener, Ann‐Kathrin Bittner, Bahriye Aktas, Lisa König, Lale Umutlu, Sven Becker and Erich Solomayer and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Oliver Hoffmann

79 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Hoffmann Germany	22	888	716	463	383	330	81	1.7k
Konstantinos Venetis Italy	22	746 0.8×	350 0.5×	316 0.7×	196 0.5×	295 0.9×	70	1.2k
Eric Hau Australia	16	324 0.4×	478 0.7×	428 0.9×	286 0.7×	385 1.2×	54	1.3k
Kathleen Lambein Belgium	18	743 0.8×	427 0.6×	578 1.2×	180 0.5×	133 0.4×	41	1.5k
Elham Sajjadi Italy	20	654 0.7×	285 0.4×	262 0.6×	186 0.5×	240 0.7×	55	1.0k
Rosa Fonti Italy	23	560 0.6×	289 0.4×	489 1.1×	387 1.0×	276 0.8×	65	1.6k
Christoph Domschke Germany	23	835 0.9×	494 0.7×	261 0.6×	184 0.5×	196 0.6×	64	1.6k
Gro Wiedswang Norway	20	1.1k 1.2×	763 1.1×	374 0.8×	95 0.2×	338 1.0×	38	1.7k
Alexandra Thomas United States	19	751 0.8×	559 0.8×	445 1.0×	107 0.3×	365 1.1×	94	1.5k
Samuele Massarut Italy	21	558 0.6×	794 1.1×	292 0.6×	316 0.8×	238 0.7×	67	1.5k
Marzia Locatelli Italy	17	757 0.9×	535 0.7×	329 0.7×	135 0.4×	221 0.7×	36	1.2k

Countries citing papers authored by Oliver Hoffmann

Since Specialization

Citations

This map shows the geographic impact of Oliver Hoffmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Hoffmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Hoffmann more than expected).

Fields of papers citing papers by Oliver Hoffmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Hoffmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Hoffmann. The network helps show where Oliver Hoffmann may publish in the future.

Co-authorship network of co-authors of Oliver Hoffmann

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Hoffmann. A scholar is included among the top collaborators of Oliver Hoffmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Hoffmann. Oliver Hoffmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harbeck, Nadia, Michael Braun, Oleg Gluz, et al.. (2024). Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.. Journal of Clinical Oncology. 42(16_suppl). TPS631–TPS631. 2 indexed citations

Göbel, Andy, Tilman D. Rachner, Oliver Hoffmann, et al.. (2024). High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer. Archives of Gynecology and Obstetrics. 309(6). 2789–2798. 3 indexed citations

Möller, Kathleen, Oliver Hoffmann, Ehsan Safai Zadeh, et al.. (2023). Comments and illustrations of the WFUMB CEUS liver guidelines: Peliosis hepatis and porphyria. Medical Ultrasonography. 26(2). 178–178. 5 indexed citations

Morawitz, Janna, Nils Martin Bruckmann, Frederic Dietzel, et al.. (2023). Conventional Imaging, MRI and 18F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer. Cancers. 15(14). 3646–3646. 3 indexed citations

Harbeck, Nadia, Ronald Kates, Timo Schinköthe, et al.. (2023). Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treatment Reviews. 121. 102631–102631. 6 indexed citations

Kasimir‐Bauer, Sabine, Mitra Tewes, Hans‐Christian Kolberg, et al.. (2023). Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer. Scientific Reports. 13(1). 21262–21262. 7 indexed citations

Umutlu, Lale, Julian Kirchner, Nils Martin Bruckmann, et al.. (2022). Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers. 14(7). 1727–1727. 31 indexed citations

Bruckmann, Nils Martin, Janna Morawitz, Frederic Dietzel, et al.. (2022). Lung Nodules Missed in Initial Staging of Breast Cancer Patients in PET/MRI—Clinically Relevant?. Cancers. 14(14). 3454–3454. 2 indexed citations

Morawitz, Janna, Nils Martin Bruckmann, Frederic Dietzel, et al.. (2021). Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 49(3). 992–1001. 39 indexed citations

10.

Müller, Volkmar, Maggie Banys‐Paluchowski, Thomas W. P. Friedl, et al.. (2021). Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 6(6). 100299–100299. 45 indexed citations

11.

Morawitz, Janna, Nils Martin Bruckmann, Frederic Dietzel, et al.. (2021). Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including ¹⁸F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard. Journal of Nuclear Medicine. 62(12). 1677–1683. 10 indexed citations

12.

Rüsch, P, et al.. (2020). Zinc distribution within breast cancer tissue of different intrinsic subtypes. Archives of Gynecology and Obstetrics. 303(1). 195–205. 30 indexed citations

13.

Demircioğlu, Aydın, Johannes Grueneisen, Marc Ingenwerth, et al.. (2020). A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer. PLoS ONE. 15(6). e0234871–e0234871. 37 indexed citations

14.

Kirchner, Julian, Ole Martin, Lale Umutlu, et al.. (2020). Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients – A prospective evaluation of staging algorithms. European Journal of Radiology. 128. 108975–108975. 14 indexed citations

15.

Bruckmann, Nils Martin, Lino M. Sawicki, Julian Kirchner, et al.. (2020). Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2816–2825. 19 indexed citations

16.

Rachner, Tilman D., Sabine Kasimir‐Bauer, Andy Göbel, et al.. (2018). Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clinical Cancer Research. 25(4). 1369–1378. 29 indexed citations

17.

Hoffmann, Oliver, et al.. (2015). Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up. Archives of Gynecology and Obstetrics. 292(5). 1117–1125. 10 indexed citations

18.

Kasimir‐Bauer, Sabine, Oliver Hoffmann, D. Wallwiener, Rainer Kimmig, & Tanja Fehm. (2012). Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Research. 14(1). R15–R15. 241 indexed citations

19.

Fehm, Tanja, Oliver Hoffmann, Bahriye Aktas, et al.. (2009). Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Research. 11(4). R59–R59. 193 indexed citations

20.

Hauth, E, et al.. (2008). Die Magnetresonanztomographie in der Diagnostik von Brustimplantaten: Eine Übersicht. Gyn�kologisch-geburtshilfliche Rundschau. 48(2). 76–83. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact